Clinical trials: Second Line Treatment
Pancreatic Cancer
Perifosine in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally…
- Trial name
- NCT00053924
- Testing
- perifosine
- Where
- 3 sites in Canada
- Sponsor
- University Health Network, Toronto
Lung Neoplasms, Carcinoma, Non-small Cell Lung
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
This is a Phase 2 study being conducted at multiple centers in the United States and Germany. Patients having non-small cell lung cancer that has spread to other parts of the body (i.e., metastatic) or is locally advanced (i.e.…
- Trial name
- NCT00094094
- Testing
- axitinib
- Where
- 11 sites in United States, Germany
- Volunteers
- 32 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, OMP-21M18, when given in combination with FOLFIRI, a standard drug treatment for advanced colorectal cancer.
- Trial name
- NCT01189942
- Testing
- OMP-21M18
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients…
- Trial name
- NCT06202001
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Endometrial Cancer
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
- Trial name
- NCT06584032
- Testing
- fruquintinib, sintilimab, paclitaxel
- Where
- 17 sites in China
- Volunteers
- 412 people
- Sponsor
- Hutchmed
Breast Cancer
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Eligible patients must receive vinorelbine plus capecitabine, with or without trastuzumab, until disease progression or unbearable toxicity.
- Trial name
- NCT00130507
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Spanish Breast Cancer Research Group
Lung Cancer, Non-Small Cell
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior…
- Trial name
- NCT00528281
- Testing
- Lapatinib, Pemetrexed
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Pancreatic Neuroendocrine Tumor With Liver Metastases
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving…
- Trial name
- LEN-pNET (NCT07835893)
- Testing
- Lenvatinib, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellulcar Carcinoma
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
While immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment…
- Trial name
- NCT07238881
- Testing
- Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
This randomized clinical trial is studying the side effects of oregovomab and to see how well it works with or without cyclophosphamide in treating patients with stage III or stage IV ovarian epithelial cancer, fallopian tube…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage III Ovarian Cancer
- Trial name
- NCT00551265
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oregovomab
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Metastatic Prostate Cancer
Second-line Chemotherapy in Castration Resistant Prostate Cancer
This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients previously treated with docetaxel containing regimen.
- Trial name
- ProstyII (NCT01558219)
- Testing
- cabacitaxel
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- Tampere University Hospital
Metastatic Breast Cancer
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.
- Trial name
- NCT02362230
- Testing
- Icotinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sun Yat-sen University
Advanced Colorectal Cancer
Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol. 2.
- Trial name
- NCT05035914
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Genital Neoplasms, Female, Fallopian Tube Neoplasms
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment.
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00191607
- Testing
- Gemcitabine, liposomal doxorubicin
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Advanced Gastric Cancer
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
This is an open-label, Phase 1b study which will be conducted in two parts: part A is the dose escalation study while part B is dose expansion study.
- Trial name
- NCT03286244
- Testing
- CM082 plus paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- AnewPharma
Non-small Cell Lung Cancer
Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in about approximately 2% of non-small cell lung cancers.Pyrotinib is an oral tyrosine kinase…
- Trial name
- NCT02535507
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji University
Colorectal Neoplasms Malignant
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.
- Trial name
- NCT06643793
- Testing
- Irinotecan liposome (ll) + 5-FU/LV + bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Ovarian Cancer
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or…
- Trial name
- NCT00034151
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Volunteers
- 52 people
- Sponsor
- Achieve Life Sciences